Capricor Therapeutics Rises as FDA Extends Review for Deramiocel

Key Facts

In a move reflecting regulatory flexibility toward biotech innovation, Capricor Therapeutics stock rose following the FDA's decision to extend the review timeline for its lead candidate, deramiocel. According to reports, the agency has pushed the review deadline to November 22, 2026. This extension follows the submission of new Phase 3 data from the HOPE-3 study, providing regulators more time for a comprehensive evaluation.

The extension is viewed as a positive development for the company, particularly as it follows previous setbacks with an advisory panel. By allowing the inclusion of updated Phase 3 data, the move is seen as reducing the immediate risk of rejection for the company's primary clinical asset. Per market context, this additional window allows for a more robust regulatory submission, though specific numeric price levels are currently unavailable in the latest data snapshot.

Investors should look toward November 22, 2026, as the definitive catalyst for the stock's next major move. In the broader market, upcoming US economic data including Building Permits and Housing Starts scheduled for August 2026 will be monitored for their impact on general market sentiment, which often influences the volatile biotech sector.